Target Discovery to Candidate Selection and Beyond
Supporting stand-alone and integrated projects
Comprehensive platform from target ID to drug candidates
Target Identification and Validation
Finding druggable targets
Comprehensive coverage of target classes and therapeutic modalities
Hit Identification
Screening services to accelerate drug discovery
Integrated platform with diverse methods to identify hit compounds
Hit Validation and Early Optimization
Confirming chemistry tractability
In vitro screening platform to support medicinal chemistry
Lead Discovery Services
Enhancing the most promising compounds
In vivo services to accelerate drug discovery
Preclinical Drug Development
Enabling the selection of the best candidates
Integrated platform for preclinical R&D to accelerate timelines
Investigational New Drug Discovery
Comprehensive IND enabling testing platform
Supporting clients from research to market
Latest Science
Discovery Newsletter Special New Year Edition 2023
Top 2022 publications, latest news and webinars
LEARN MORE >Introduction into Fragment Based Drug Discovery
This webinar gives insight into this technology and show how FBDD can be successfully applied for the identification of novel...
LEARN MORE >OncoWuXi Newsletter November 2022
CD79B-targeted ADC related models and Ovalbumin-induced rheumatoid arthritis in rabbits
LEARN MORE >Discovery Newsletter November 2022
🧬 SITC posters, Peer-reviewed Publications, Fragment Based DD & Oligonucleotide Discovery Webinars & More!
LEARN MORE >PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances...
Poster | PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System
LEARN MORE >Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor...
Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses
LEARN MORE >Intra-carotid artery brain metastasis models for the evaluation of lung...
Non-CNS metastatic brain cancer is about 10 times more common than CNS cancer. Lung cancer and breast cancer account for...
LEARN MORE >Developing drug-induced resistant tumor models for efficacy evaluation of next-generation...
The therapeutic landscape of cancer has been transformed over the last few decades. Our understanding of cancer and its therapeutic...
LEARN MORE >Developing a panel of orthotopic syngeneic tumor models for IO...
Immuno-oncology (IO) therapy is the focus of drug discovery in recent years. Unlike chemotherapy or targeted agents, the pharmacological efficacy...
LEARN MORE >Development of an integrated in vitro and in vivo OVA-specific...
As the development of cancer immunotherapy and urgent demand of precision medicine, cancer vaccines have been envisioned as a novel...
LEARN MORE >Mouse hind limb tumor metastatic model to evaluate prophylaxis and...
Bone metastasis is one organ specific metastasis that cause severe pain and immobility, also increase mortality, lots of prophylaxis and...
LEARN MORE >Establishment of spatial transcriptomics assay to find the mechanism of...
Intra-tumor heterogeneity is one of the biggest challenges in cancer treatment today, not only on cell types and functions, but...
LEARN MORE >Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of...
Ionizing radiation has largely been recognized as a local targeted therapy by a variety of mechanisms, including inducing direct DNA...
LEARN MORE >The critical platforms of PROTAC validation
In recent years, proteolysis targeting chimeric (PROTAC) technology has become an effective endogenous protein degradation tool in drug discovery. As...
LEARN MORE >Enabling Technology for Targeted Protein Degradation
Traditional small molecule therapeutic mechanisms have recently been augmented by a new strategy to specifically manipulate the levels of disease-related...
LEARN MORE >